{"contentid": 488767, "importid": NaN, "name": "Tagrisso goes full steam ahead with new EU approval", "introduction": "Targeted therapies have been a game changer in EGFR-mutated lung cancer, with options such as Tagrisso (osimertinib), from AstraZeneca, helping to greatly improve progression-free survival (PFS).", "content": "<p>Targeted therapies have been a game changer in EGFR-mutated lung cancer, with options such as Tagrisso (osimertinib), from AstraZeneca (LSE: AZN), helping to greatly improve progression-free survival (PFS).</p>\n<p>Now the treatment has secured a new approval in Europe, for the adjuvant treatment of certain adults with early-stage non-small cell lung cancer (NSCLC), as defined by a biomarker test.</p>\n<p>The approval, which comes several months after the US regulator gave its blessing, will enable many people to be treated in an earlier and potentially more curative stage of disease.</p>\n<p>Tagrisso is already greatly overshooting chief executive Pascal Soriot&rsquo;s initial goal of $ billion in annual sales.</p>\n<p>The treatment, a key plank of AstraZeneca&rsquo;s new intent to focus heavily on the high-impact field of oncology, saw sales increase 17% in the first quarter to $1.1 billion, with overall revenues in 2020 well exceeding $4 billion.</p>\n<h2>New approval</h2>\n<p>The recent approval by the European Commission was based on positive results from the ADAURA Phase III trial in which Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS).</p>\n<p>The trial also showed a statistically-significant and clinically-meaningful improvement in DFS for Tagrisso in the overall trial population, a key secondary endpoint.</p>\n<p>Margarita Majem of the Hospital de la Santa Creu i Sant Pau said the approval would likely &ldquo;change clinical practice in the EU,&rdquo; adding the therapy has shown &ldquo;an unprecedented disease-free survival benefit for patients with EGFR mutations.&rdquo;</p>\n<p>Dave Fredrickson, executive vice president for oncology, said: &ldquo;We know the earlier a patient&rsquo;s cancer is detected and treated, the greater chance they may have of being cured, which is why this approval is significant.&rdquo;</p>\n<p>Tagrisso is now approved to treat early-stage lung cancer in more than fifty countries, including in the USA and China, and additional global regulatory reviews are ongoing.</p>\n<p>Tagrisso is also approved for the first-line treatment of people with locally advanced or metastatic EGFRm NSCLC and for the treatment of locally advanced or metastatic EGFR T790M mutation-positive NSCLC in the EU, the USA, Japan, China and many other countries.</p>\n<p>&nbsp;</p>", "date": "2021-05-28 10:06:00", "meta_title": NaN, "meta_keywords": "Tagrisso, approval, cancer, lung, survival, treatment, greatly, full, steam, game, EGFR-mutated, therapies, Targeted, options, osimertinib, AstraZeneca", "meta_description": "Targeted therapies have been a game changer in EGFR-mutated lung cancer, with options such as Tagrisso (osimertinib), from AstraZeneca, helping to greatly impro", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-28 09:47:53", "updated": "2021-05-28 10:06:49", "access": NaN, "url": "https://www.thepharmaletter.com/article/tagrisso-goes-full-steam-ahead-with-new-eu-approval", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "tagrisso_big.jpg", "image2id": "tagrisso_small-1-.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Oncology", "topic_tag": "European Medicines Agency, Focus On, Regulation, Research", "geography_tag": "Europe, UK", "company_tag": "AstraZeneca", "drug_tag": "Tagrisso", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-28 10:06:00"}